Coya Therapeutics股票讨论区

$Coya Therapeutics (COYA.US)$ 路透社· 1分钟前
Coya Therapeutics宣布，经皮给药的Coya 302在帕金森病的预临床炎症小鼠模型中引发了对脑部的直接抗炎效应

$Coya Therapeutics (COYA.US)$
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302significantly reduces neuroinflammation in key brain regions affected b...

$Coya Therapeutics (COYA.US)$
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on...

$Coya Therapeutics (COYA.US)$
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protectionfor the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs).
This combination aims to enhance regulatory T cell function and may offer a mul...

$Coya Therapeutics (COYA.US)$ 路透社·
Coya治疗：收到FDA通知称，在启动Coya 302 ALS研究之前需要额外的非临床数据。

$Coya Therapeutics (COYA.US)$ Coya Therapeutics扩大在休斯敦方法医学研究院的赞助研究合作，并获得约翰逊细胞治疗中心的资助，推进调控性t细胞外泌体平台进入临床阶段

$Coya Therapeutics (COYA.US)$ Coya Therapeutics宣布在《神经科学前沿》杂志上发表了有关CTLA4-Ig和白细胞介素-2组合疗法用于ALS的第1期研究
Benzinga· 2分钟前
数据显示，患有肌萎缩侧索硬化症（ALS）的患者在24周（6个月）时疾病进展停滞，并且治疗组患者中炎症、氧化应激的持续减少，以及调节性T细胞（Treg）数量和抑制功能增强。

$Coya Therapeutics (COYA.US)$
Coya Therapeutics宣布在医学期刊《神经学前沿》上发表同行评议的手稿
Coya Therapeutics（纳斯达克：COYA）宣布同行评议的手稿在《神经学前沿》上被接受。这项名为“奥美特尔肌萎缩侧索硬化症的第1阶段概念验证研究评价了CTLA4-Ig和白细胞介素-2联合疗法的安全性，耐受性和生物标记物反应”的研究突出了ALS的停止进展...

$Coya Therapeutics (COYA.US)$
NEWS
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Positive
Completion of Phase 2 study on schedule.
Study funded by the Gates Foundation and Alzheimer’s Association, indicating strong support.
Topline results expected by summer 2024.
Preliminary data showed significant improvements in cognitive function.
Significant enhancement in regulatory T cell (Treg) function and...

$Coya Therapeutics (COYA.US)$ Coya Therapeutics Inc -Phase 2 Top Line Data on Track to Be Reported in Summer of 2024